Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

v3.23.3
LIQUIDITY (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Accumulated deficit   $ (275,509)   $ (260,985)
Net loss   (14,524) $ (9,831) (51,800)
Net cash used in operating activities   (10,585) $ (7,589) (44,500)
Cash and cash equivalents   8,057   16,036
Short-term investments   90,673   85,860
Long-term investments   8,144   16,470
Total liabilities   9,435   7,549
Current liabilities   7,195   $ 5,200
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon First Dosing Of The First Patient [Member]        
Milestone closing payment $ 5,000 5,000    
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient [Member]        
Milestone closing payment   $ 5,000